1. Introduction {#s1}
===============

Major depressive disorder (MDD), primarily described in terms of emotional features such as depressed mood,^[@R2],[@R30]^ also includes physical symptoms (eg, idiopathic pain, changes in weight, sleep, appetite)^[@R20],[@R22],[@R35],[@R45]^ that are the major complaints driving patients seeking medical care.^[@R16],[@R21],[@R35],[@R52]^ Painful physical symptoms (PPS), generally present as unexplained headache, pain in the joints or abdomen, or pains in the chest, neck, or shoulder areas, are frequently encountered physical symptoms.^[@R6],[@R20],[@R21],[@R26]^ PPS is linked with poorer clinical outcomes and contribute to the overall burden of MDD.^[@R8],[@R12],[@R29],[@R34],[@R37]^

Some studies suggest that the depressive symptoms (DS) and PPS present different trajectories.^[@R22],[@R40],[@R48]^ For example, MDD patients with PPS receiving serotonin-selective reuptake inhibitors for 9 months initially showed similar improvements in both DS and PPS. However, while DS continued to improve, PPS did not improve further after 1 month.^[@R28]^

Duloxetine is balanced in its affinity of binding to serotonin and norepinephrine transporter sites and potently inhibits serotonin and norepinephrine reuptake, thus enhancing monoaminergic tone.^[@R11],[@R32],[@R60]^ Randomized, double-blind placebo-controlled trials with MDD patients with PPS showed that duloxetine is effective in improving both DS and PPS.^[@R7],[@R8]^ However, the extent of interactions between DS and PPS improvement in MDD is not well understood, and the reciprocal roles of pain relief and relief of DS on each other in MDD patients are currently under investigation.^[@R40]^

For example, in a 9-week treatment of MDD patients with duloxetine, 51% of duloxetine\'s total effect on overall pain was due to a direct effect and 49% was the result of an indirect effect mediated through change in depression severity.^[@R22]^ However, because not all the patients necessarily had PPS associated with MDD, these results may not be applied to the specific population of patients with MDD and associated PPS.

In a different study,^[@R50]^ the effect of an 8-week treatment with duloxetine in a population screened for MDD with PPS indicated that 59% of the likelihood of remission of MDD was because of the direct effect of treatment while indirect effect through pain reduction accounted for 41% of the effect. Although this study clarified the attribution of PPS improvement toward remission in patients with MDD, the path analysis was performed only at a single time point after treatment initiation; therefore, the time course of depression improvement indirectly attributed to PPS improvement over time remained unexamined.

To the best of our knowledge, time-related changes in the relative contributions of the direct effect of duloxetine on PPS and indirect effect on PPS via DS improvement, or of the reverse situation, have not been studied. Therefore, the present investigation was undertaken to ascertain the relative contributions of PPS and of DS at several time points after beginning duloxetine treatment for patients with MDD using path analysis.

2. Methods {#s2}
==========

2.1. Data sources and study selection {#s2-1}
-------------------------------------

The Eli Lilly clinical trial database contains all clinical trials of duloxetine for patients with MDD that were conducted by Eli Lilly and Company or its partners outside Japan. We reviewed this database and selected randomized, double-blind parallel-group clinical trials that included duloxetine (≤60 mg/d) or placebo for the acute treatment of MDD with associated PPS. Studies using duloxetine 60 mg/d were chosen because this dose has been confirmed as effective in the treatment of MDD and is commonly used globally.^[@R8],[@R17]^ As a result, a total of the following 4 studies were initially identified: HMDH,^[@R10]^ HMGR,^[@R25]^ HMGU,^[@R24]^ and HMCB.^[@R9]^ No studies meeting these criteria were excluded. For the evaluation of pain severity, all studies used the same scale, Brief Pain Inventory-Short Form (BPI-SF).^[@R13]--[@R15]^ However, for the evaluation of DS, 3 studies, namely HMDH, HMGR, and HMGU, used the Montgomery--Åsberg Depression Rating Scale (MADRS)^[@R43]^ and 1 study, HMCB, used the Hamilton Rating Scale for Depression. Because our aim was to conduct patient-level integrated analysis using the same analysis method and scales across studies, we included the former 3 studies (ie, HMDH, HMGR, and HMGU) in the analysis and excluded the latter 1 study (ie, HMCB) from the analysis.

The common inclusion criteria for the 3 included studies HMDH, HMGR, and HMGU (Table [1](#T1){ref-type="table"}) were male or female outpatients aged at least 18 years who met the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition^[@R1]^ criteria for MDD and had MADRS ≥20, at least moderate pain based on BPI-SF average pain score ≥3, and a Clinical Global Impression of Severity score ≥4. Exclusion criteria included the following: current Axis I disorder (other than MDD), history of bipolar disorder, schizophrenia, or other psychotic disorders; any diagnosed pain syndrome as per medical history (for HMDH) or presence of pain of a known origin (for HMGR and HMGU). The primary efficacy outcome measure for HMDH was BPI-SF average pain score, and the primary efficacy outcome measures for HMGR and HMGU were BPI-SF average pain score and MADRS total score. For all studies, data were collected at baseline and on weeks 1, 2, 4, and 8. Trial HMDH also included data collection on week 6. The studies are summarized in Table [1](#T1){ref-type="table"}.

###### 

Pooled studies used in this path analysis.

![](jop-157-577-g001)

The protocol was approved by the appropriate ethical review boards for each of the study centers. Patients gave written informed consent before participating in the studies. The studies were all conducted in accordance with the regulatory standards in each country and conformed to the standards dictated by Good Clinical Practice and the Declaration of Helsinki.^[@R4]^ The studies were registered at [clinicaltrials.gov](http://clinicaltrials.gov) (NCT00191919, NCT01070329, and NCT01000805).

2.2. Treatment {#s2-2}
--------------

Across 3 studies, all the enrolled patients were randomized to an oral dose of 60 mg/d of duloxetine or placebo. Patients randomly assigned to duloxetine 60 mg/d started on duloxetine 30 mg/d for 1 week and then were titrated up to duloxetine 60 mg/d for 7 weeks, followed by a 2-week taper period for HMDH or an optional taper-off period for HMGR and HMGU.

2.3. Assessments {#s2-3}
----------------

To evaluate improvement in DS, change in MADRS total score from baseline was assessed. The MADRS is a rating scale for depression, and it uses 10 core symptoms of depression that are rated on a scale of 0 to 6 for a total maximal score of 60.

To evaluate improvement in PPS, change in BPI-SF average pain score from baseline was assessed. This inventory was designed to assess pain intensity and its interference with activities of daily living. The questionnaire uses a 0 (no pain or does not interfere) to 10 (pain as severe as you can imagine or completely interferes) scale and is a self-assessment tool used by the patient.^[@R13]--[@R15]^ For the purposes of the present investigation, only responses to BPI-SF item 5, 24-hour average pain score, were considered, because this was the primary outcome measure for pain used in studies HMDH, HMGR, and HMGU.^[@R10],[@R24],[@R25]^ Moreover, the single item, average pain score, is commonly used in randomized clinical trials for the assessment of pain relief,^[@R5],[@R27],[@R51],[@R53],[@R57]^ and its use is endorsed by the IMMPACT recommendations for clinical pain trials^[@R18],[@R19],[@R53],[@R58]^ as well as by the FDA Draft Guidance for Industry: Patient-Reported Outcome Measures.^[@R23]^ Depression (MADRS) and average pain score (BPI-SF) were assessed at baseline (Day 0) and at 1, 2, 4, and 8 weeks of treatment.

Path analysis is related to multiple regression methods and is a means to decompose correlations to determine the correlations among variables on an effect. In the present investigation, path analysis was first performed to determine the direct effect of duloxetine treatment on PPS and the indirect effects on PPS due to DS improvement over time. An alternate path analysis was performed to determine the direct effect of duloxetine treatment on DS improvement and the indirect effect on DS through PPS improvement over time. The analyses were performed at 1, 2, 4, and 8 weeks.

2.4. Statistical methods {#s2-4}
------------------------

All randomized patients with MADRS total score ≥20 and with BPI-SF average pain score ≥3 who received placebo or duloxetine (60 mg/d) were included in the analyses. Patients for whom there were no baseline MADRS data, or no baseline BPI-SF baseline data, or for whom there were no post--baseline MADRS or BPI-SF data were not included in the analyses. The measures of efficacy were based on a mixed-effects model repeated-measures approach. The model included the fixed effects of "study," "treatment," "week," "baseline," "treatment-by-week interaction," and "baseline-by-week interaction." All statistical tests were conducted at the significance level of 2-sided 5%, and no adjustments for multiplicity were conducted.

The path analyses used in this analysis are based on previously described studies.^[@R40],[@R50]^ Path analyses were performed with 2 path analysis models. The primary path analysis was performed to examine the direct and indirect treatment effect on PPS improvement. In this case, the prespecified causal relationships were defined as treatment having a direct effect on PPS improvement and an indirect effect on PPS improvement due to DS improvement. In this path analysis model (Figure [1](#F1){ref-type="fig"}A), PPS improvement and DS improvement were described with the following 2 linear regression models:and

![(A) Path analysis diagram that illustrates direct and indirect effects of treatment on PPS improvement. (B) Path analysis results showed a marked direct effect of treatment on PPS improvement at 1 and 2 weeks of treatment. The relationship was reversed for 4 and 8 weeks, indicated by the marked indirect effect by way of DS improvement. DS, depressive symptoms; PPS, physical pain symptoms; w, week(s).](jop-157-577-g004){#F1}

The direct and indirect effects were calculated as % of the total from models 1 and 2 such that:and

For each week where the analyses were performed, PPS or DS improvement was defined as the "Change from baseline in BPI-SF average pain score/MADRS total score" at that week.

An alternate path analysis model was evaluated where the prespecified causal relationships were defined as treatment having a direct effect on DS improvement and an indirect effect on DS improvement due to PPS improvement. In this path analysis model (Figure [2](#F2){ref-type="fig"}A), DS improvement and PPS improvement were described with the following 2 linear regression models:and

![(A) Path analysis diagram that illustrates direct and indirect effects of treatment on DS improvement. (B) Path analysis results showed a slightly greater indirect effect by way of PPS improvement at 1 and 2 weeks of treatment. The relationship is reversed for 4 and 8 weeks, indicated by the increased direct effect of treatment on DS improvement relative to the indirect effect by way of PPS improvement. DS, depressive symptoms; PPS, physical pain symptoms; w, week(s).](jop-157-577-g009){#F2}

The %direct and %indirect effects and the PPS or DS improvement determinations were made in the same manner as described above.

3. Results {#s3}
==========

3.1. Patient baseline characteristics {#s3-1}
-------------------------------------

A total of 1320 patients were randomly assigned to the treatment groups, resulting in 641 receiving treatment with duloxetine and 679 receiving placebo (Table [2](#T2){ref-type="table"}). Most of the patients were female (69.7%) and Caucasian (81.8%). The mean age (SD) of the patients was 46.5 (12.99) years. The mean baseline MADRS total score (SD) and BPI-SF average pain score (SD) were 29.9 (2.83) and 5.7 (1.63), respectively. Within this population, 25.5% were undergoing their first MDD episode. Gender and ethnicity distributions, age, and baseline illness characteristics were similar between duloxetine and placebo groups (Table [2](#T2){ref-type="table"}).

###### 

Baseline characteristics (all randomized patients).
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### 3.1.1. Patient disposition {#s3-1-1}

At the end of the 8-week treatment, there was no significant difference in the numbers of patients discontinued early between duloxetine and placebo groups (duloxetine: 15.9% vs placebo: 16.2%). A significantly (*P* = 0.0033) greater number of patients discontinued treatment for lack of efficacy in the placebo group (4.4%) compared with that in the duloxetine group (1.6%). There was no significant difference (*P* = 0.2261) between the duloxetine (5.3%) and placebo (3.8%) groups in discontinuation due to adverse events (Table [3](#T3){ref-type="table"}).

###### 

Patient disposition (all randomized patients).
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### 3.1.2. Depressive symptoms\' improvement over time {#s3-1-2}

Depressive symptoms measured by MADRS total score continuously decreased over the 8-week study period for both duloxetine and placebo groups (Figure [3](#F3){ref-type="fig"}A). At each time point, the reduction in MADRS total score for patients receiving duloxetine was significantly greater than the decrease in MADRS total score experienced by the placebo group (Figure [3](#F3){ref-type="fig"}A). In addition, the difference in MADRS score reduction between the duloxetine group and the placebo group increased from a least-squares mean difference (SE) of −0.72 (0.27; *P* = 0.0074) at week 1 to a mean difference (SE) of −4.46 (0.54; *P* \< 0.0001) at week 8 (Figure [3](#F3){ref-type="fig"}A).

![Change from baseline in MADRS total score (A) and BPI-SF average pain score. (B) Effect size is the LS mean estimate divided by the square root of the residual variance (\**P* ≤ 0.01; \*\**P* ≤ 0.001 MMRM). BPI-SF, Brief Pain Inventory-Short Form; LS mean, least-squares mean; MADRS, Montgomery--Åsberg Depression Rating Scale; MMRM, mixed-effects model repeated-measures.](jop-157-577-g012){#F3}

### 3.1.3. Painful physical symptoms\' improvement over time {#s3-1-3}

Likewise, a continuous significant (*P* \< 0.001) PPS improvement as measured by BPI-SF average pain score was observed in duloxetine and placebo groups throughout the 8-week trial period (Figure [3](#F3){ref-type="fig"}B). The difference in BPI-SF scores between duloxetine and placebo groups increased over time from a least-squares mean difference (SE) of −0.35 (0.09; *P* = 0.0001) at week 1 to a mean difference (SE) of −0.76 (0.14; *P* \< 0.0001) (Figure [3](#F3){ref-type="fig"}B).

### 3.1.4. Path analyses---direct and indirect effects on painful physical symptoms {#s3-1-4}

In the first path analysis model proposed for path analyses, the causal relationships were defined as treatment having a direct effect on PPS reduction and an indirect effect on PPS reduction due to DS improvement (Figure [1](#F1){ref-type="fig"}A). The path analysis was applied to the PPS and DS scores collected at weeks 1, 2, 4, and 8 (Figure [1](#F1){ref-type="fig"}B). At week 1, path analysis indicated that 75.3% of the improvement in PPS was attributed to a direct effect of the duloxetine treatment and the remaining 24.7% of the improvement was attributed to an indirect effect through DS improvement (Figure [1](#F1){ref-type="fig"}B). However, over time, the percentage of the direct effect on PPS improvement was reduced such that at week 8 only 22.6% of the PPS improvement was due to a direct effect of the treatment and 77.4% of the PPS improvement was attributed to the indirect effect through DS improvement (Figure [1](#F1){ref-type="fig"}B).

### 3.1.5. Path analyses---direct and indirect effects on depressive symptoms {#s3-1-5}

The alternate path analysis model defined the causal relationships as treatment having a direct effect on DS improvement and an indirect effect on DS improvement by reducing PPS (Figure [2](#F2){ref-type="fig"}A). At week 1, the direct effect of treatment on DS improvement was 46.4% and the indirect effect through PPS improvement was 53.6% (Figure [2](#F2){ref-type="fig"}B). Over time, the direct effect of treatment on DS improvement increased somewhat such that at week 8, 62.6% of the DS improvement was attributed to a direct effect of treatment and 37.4% of the DS improvement was attributed to an indirect effect by way of PPS improvement (Figure [2](#F2){ref-type="fig"}B).

4. Discussion {#s4}
=============

The results of this study show that treatment of patients who have MDD with associated PPS with 60 mg/d of duloxetine for 8 weeks results in a progressive improvement of both DS and PPS, as indicated by a reduction in MADRS total scores and BPI-SF average pain scores. At week 1, the direct effect of treatment on PPS reduction was 75% and only 25% of the PPS relief was attributed to DS improvement. The large direct component on PPS relief was also present at week 2, but the balance shifted somewhat abruptly such that the indirect effect outweighed the direct effect beginning at week 4. After 8 weeks of treatment, the PPS improvement in depressed patients with PPS was largely due to the indirect effect resulting from the DS improvement (77%) and only 23% was attributed to a direct effect of duloxetine. Accordingly, the observations made in the present investigation are consistent with earlier studies on the interactions between MDD and PPS.^[@R22],[@R28],[@R40],[@R48],[@R50]^ Importantly, this study extends these observations to show that there is a marked shift in the direct effect of duloxetine on pain relief in patients with MDD over time.

First, when assessing the attribution of the direct effect of treatment on PPS and the indirect effect via DS improvement during the acute phase treatment as a whole (eg, 8-9 weeks), this study showed a direct effect of duloxetine of only 23% and an indirect effect of 77%. When compared with a previous report by Fava et al^[@R22]^ where the direct effect of duloxetine on PPS reduction attributed 51% and the indirect effect 49%, our results indicate a lower attribution of direct effect on PPS and higher attribution on indirect effect via DS improvement. This inconsistency may be explained by the difference in population in the study. In the study by Fava et al,^[@R22]^ the patient population was not initially screened for PPS, resulting in a diverse range of pain severity, whereas our study used a specific population: patients with MDD and associated PPS. From a clinical perspective, these results suggest that, for the patients with MDD and with associated PPS, although the patients explicitly exhibit PPS, it is rather important to improve DS to achieve PPS improvement in the end.

Second, when assessing the attribution of the direct effect of treatment on PPS and indirect effect via DS improvement during the very beginning of acute phase treatment (ie, 1-2 weeks), this study reveals a new clinical perspective. This study showed that until 2 weeks of treatment the direct effect of treatment on PPS dominated over indirect effect via DS improvement. From a clinical perspective, this result suggests that, to quickly relieve the patients with MDD with associated PPS from pain symptoms in the initial phase of treatment, it is important to count on the effect of pharmacological therapy rather than to expect DS to indirectly improve PPS. This clinical implication is underscored by the larger effect size elicited by duloxetine with regard to PPS improvement and in contrast to DS improvement at weeks 1 and 2, as shown in Figure [1](#F1){ref-type="fig"}.

Third, the shift in dominance of the direct effect of duloxetine on PPS to the indirect effect over time is consistent with the known neurobiology of serotonin and norepinephrine reuptake inhibitors with respect to pain and depression. The pain relief obtained with duloxetine is of an immediate nature. Duloxetine engages descending pain modulation that is likely to be impaired among patients with MDD.^[@R39]^ Duloxetine is also clinically effective in several persistent painful conditions, such as chronic musculoskeletal pain of the back, osteoarthritis, diabetic neuropathy, and fibromyalgia.^[@R54]^ These conditions are associated with dysfunction of endogenous pain modulation, and it is highly likely that duloxetine, by enhancing noradrenergic transmission, engages descending pain modulatory systems.^[@R41],[@R46],[@R47],[@R54],[@R55]^ In contrast, the antidepressant action of these drugs is not immediate in onset but occurs after a considerable latency of 3 to 6 weeks.^[@R42]^ This latency to effect indicates that the clinical benefit is not due to an immediate elevation in the synaptic availability of norepinephrine and serotonin, but rather to neuroplastic changes that take place over time in response to the elevation in basal levels of these transmitters.^[@R44],[@R49]^ Accordingly, the predominance of the direct effect of duloxetine during the initial trial period is likely due to engagement of noradrenergic pain modulatory systems, whereas the later indirect effects are due to the antidepressant mechanisms coming online.^[@R48]^ The important clinical implication here is that pain relief with a serotonin and norepinephrine reuptake inhibitor is not simply due to alleviation of depression but due to possible engagement of descending pain modulation.

Finally, when the alternate path analyses was performed, it was found that after 8 weeks of treatment the direct effect (62.6%) of duloxetine on depression predominated over the indirect effect (37.4%). The results of this study are consistent with those of Robinson et al.^[@R50]^ In that study, which also used a pain-rich population, the MADRS remission score was used as a measure of reversal of depression, and path analysis indicated that the direct effect of duloxetine accounted for 59% of the treatment on remission and the indirect effect through pain reduction accounted for 41% after 8 weeks of treatment.^[@R50]^ This study extends these observations by revealing a shift in the predominance of indirect vs direct effects, in the opposite direction to our primary analysis. The indirect effect of duloxetine on DS through reduction of PPS predominated during the early time points, and the direct effects predominated at the later time points. Moreover, unlike the effects on pain, the difference in direct and indirect effects was much lower and the shift occurred more gradually.

We acknowledge that there are some limitations of the study that should be taken into consideration. Despite attempts to enhance diversity in the population sample, most of the patient population is Caucasian (82%) and female (70%). Potential differences due to gender, ethnicity, or cultural considerations^[@R3],[@R36]^ may be underrepresented in this sample. For example, patients with MDD in Asian cultures tend to emphasize physical symptoms over emotional ones and may report greater incidences of PPS.^[@R3],[@R38]^ In addition, there are some additional considerations regarding path analysis. Although this analysis is based on assumptions of causal relationships, in this study only PPS and DS were considered. Thus, the effects of treatment on other symptoms that may be associated with either DS or PPS but were not included in the MADRS or BPI-SF scale, such as anxiety, fatigue, or other non-PPS, were not considered separately. Accordingly, the possible contribution of other factors to the direct effect should at least be kept in mind. In addition, BPI average pain may not fully represent the character and severity of PPS, although it is commonly used for evaluation of PPS^[@R9],[@R10],[@R24],[@R25]^ and of other types of chronic pain^[@R5],[@R27],[@R51],[@R53],[@R57]^ in many randomized clinical trials. Another limitation of the study is that only a single dose, 60 mg/d, of duloxetine was included, and higher doses of duloxetine may have different effects on both DS and PPS. However, it should be noted that a number of randomized clinical trials that included direct comparisons between 60 and 120 mg/d of duloxetine for MDD^[@R33]^ and painful diabetic neuropathy or fibromyalgia^[@R5],[@R27],[@R31],[@R56],[@R59]^ lead us to suggest that the higher (ie, 120 mg/d) dose of duloxetine is not likely to lead to different results in this study. We also believe that by conducting patient-level integrated analysis for 3 studies with the same analysis method and scales, it is expected that this would produce higher internal validity and reproducibility.

In conclusion, this study advances our understanding of the potential interaction between DS and PPS in MDD. To the best of our knowledge, there are no other published studies available where the attribution of DS and of PPS in MDD was examined over time. Moreover, the patient population selected included only patients with PPS of at least moderate severity, allowing a more rigorous examination of the interaction between pain and DS. The results of this study showed that duloxetine produced a large direct effect on pain relief during the initial 2 weeks of treatment. During this stage, the improvement in PPS in patients with MDD was likely not due to a reduction in DS, but rather to engagement of endogenous noradrenergic pain modulatory systems. In contrast, the reduction in PPS during the latter stage of treatment was likely due more to DS improvement. This dynamic shift provides context for proposing that both the DS and PPS in patients with MDD should be addressed simultaneously at treatment initiation, rather than focusing only on the DS with the idea that improvement in pain will spontaneously follow.
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